Jessica Robinson-Papp, MD, MS, professor of neurology at the Icahn School of Medicine at Mount Sinai, talks about the strides made in antiretroviral therapy for HIV and how these improvements lead to better patient outcomes.
Clinical guidelines highlight the importance of medication adherence and early treatment of HIV, and this can help with potential neurological complications; newer antiretrovirals are also easier to tolerate, says Jessica Robinson-Papp, MD, MS, professor of neurology at the Icahn School of Medicine at Mount Sinai.
Transcript
How can neurologic complications be prevented in patients with HIV, and how can we ensure patients are taking these steps?
The most important thing is medication adherence and early medication and early treatment of HIV, which is what the clinical guidelines are now. The guidelines that we follow is that when someone is first diagnosed positive, then they should go on treatment and they should stay on treatment. That will help with the neurologic complications as well, and of course when we move toward trying to find cures for HIV that should hopefully help even more.
Some of what we see is a bit of a legacy effect, because some of our older patients are also the same patients who were infected over very long periods of time and are also the same patients who were infected very early in the epidemic. Those people probably experienced more immunosuppression because there wasn't treatment at the beginning and then they also experienced some of the suboptimal therapies that were there in the very beginning that had more toxicity.
A lot of our older antiretrovirals had significant neurotoxicity; they don't anymore. So, we're hopeful that patients who are infected later and people who are being infected now won't have as many neurologic complications to begin with because the care will be started sooner and will be more effective and easier to tolerate.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
A Focus on Women: AUA Best Posters Highlight Female Athletes, Prenatal Care, and Women in Urology
May 9th 2024Three posters from the American Urological Association (AUA) 2024 Annual Meeting focused on urinary incontinence in female athletes, prenatal care for fetuses with spina bifida in California, and the experiences of women residents at the Brady Urological Institute.
Read More